Compare Cassava Sciences Inc (FLNA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs T Rowe Price Group Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while T Rowe Price Group Inc trades at $119.35 (market cap $25.41B). The key difference: T Rowe Price Group Inc is far larger — about 478.2× Cassava Sciences Inc's market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TROW | |
|---|---|---|
Market Cap | $53.14M | $25.41B |
Sector | Health | Financials |
52-Week High | $4.64 | $120.16 |
52-Week Low | $1.09 | $86.19 |
Enterprise Value | -$33.43M | $22.12B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
T. Rowe Price (TROW) trades at $116.07, up 2.13% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 12.72, net income margin of 28.28%, and consistent earnings beats. Recent AUM growth to $1.89 trillion and strategic institutional enhancements support positive momentum. Technical indicators show the stock trading near pivot point resistance at $116 with support at $115.
TROW presents a compelling value opportunity with attractive valuation metrics and strong profitability. The primary risk remains equity outflows despite diversification efforts. Analyst consensus is cautious with 63% hold ratings, though recent Zacks upgrades to Strong Buy highlight growing optimism. The stock's current price sits above the consensus target of $109.17, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
